Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
18 juil. 2023 07h03 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
29 juin 2023 17h04 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
16 juin 2023 07h38 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease,...
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
16 mai 2023 08h29 HE
|
Unicycive Therapeutics, Inc.
Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones Continued progress...
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
24 avr. 2023 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs,...
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
31 mars 2023 07h00 HE
|
Unicycive Therapeutics, Inc.
Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Financing by new and existing institutional...
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
06 mars 2023 07h00 HE
|
Unicycive Therapeutics, Inc.
$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and...
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
27 févr. 2023 07h00 HE
|
Unicycive Therapeutics, Inc.
Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute...
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
02 févr. 2023 08h30 HE
|
Unicycive Therapeutics, Inc.
Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., Feb. 02, 2023 (GLOBE...
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
23 janv. 2023 07h00 HE
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...